Payment overview · 2025
General Payments
$4,426.15
199 reported records · 55 companies
Healthcare provider profile · identity verified
Srinivas Kodali, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BEAUMONT, TX · NPI 1295979813
Verified facts
What the public records show
CMS Open Payments records show Srinivas Kodali, M.D received $4,426.15 in general payments during 2025 across 199 reported records.
Merck Sharp & Dohme LLC accounted for 8.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 91 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabometyx, Calquence, Erleada, Venclexta, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
Exelixis Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABOMETYX as an associated drug or biological on 11749 records involving 4526 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Cabometyx by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 790 records involving 308 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Erleada by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $371.67 | 8.4% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $338.38 | 7.7% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $288.41 | 6.5% | 15 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $261.43 | 5.9% | 12 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $256.29 | 5.8% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $240.69 | 5.4% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $207.47 | 4.7% | 9 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $185.22 | 4.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.52 | 3.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.86 | 3.6% | 8 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $139.58 | 3.1% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $129.28 | 2.9% | 7 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.93 | 2.3% | 4 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $82.81 | 1.9% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $78.74 | 1.8% | 4 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.51 | 1.7% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $70.80 | 1.6% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $67.61 | 1.5% | 2 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $66.30 | 1.5% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $63.96 | 1.4% | 3 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $63.89 | 1.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.50 | 1.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.16 | 1.2% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $49.98 | 1.1% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $49.78 | 1.1% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $48.59 | 1.1% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $47.94 | 1.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $45.31 | 1.0% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $43.67 | 1.0% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.55 | 1.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.20 | 0.9% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $39.79 | 0.9% | 3 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $36.97 | 0.8% | 2 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $28.95 | 0.7% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $27.86 | 0.6% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.81 | 0.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.73 | 0.6% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.39 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.13 | 0.6% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $24.40 | 0.6% | 1 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $23.92 | 0.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.42 | 0.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $21.74 | 0.5% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $21.11 | 0.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.02 | 0.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $20.81 | 0.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.47 | 0.5% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $18.46 | 0.4% | 1 | 2025 |
| Nuvation Bio Inc. | Unresolved — no canonical attribution shown | $18.04 | 0.4% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $17.30 | 0.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.4% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $15.84 | 0.4% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $13.72 | 0.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.47 | 0.3% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $13.47 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,393.89 | 197 |
| Education | $32.26 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $263.29 | 15 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $254.67 | 10 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $207.47 | 9 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $200.50 | 9 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $185.22 | 8 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.86 | 8 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $129.10 | 5 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $125.12 | 5 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $125.12 | 5 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $122.53 | 6 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $104.09 | 4 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $100.93 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $98.15 | 4 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $90.50 | 4 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $89.24 | 4 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.89 | 5 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $82.86 | 3 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $82.81 | 3 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $81.17 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $74.81 | 4 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $74.51 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $73.85 | 3 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $72.97 | 3 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $72.28 | 6 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $70.80 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $68.02 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $68.02 | 3 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $66.30 | 4 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $65.37 | 3 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $65.37 | 3 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $65.37 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $63.89 | 3 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $63.89 | 3 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $63.21 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $61.00 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $60.18 | 3 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $56.99 | 3 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $53.50 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $53.50 | 2 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $49.98 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $48.71 | 2 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $48.59 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $47.40 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $45.77 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $44.38 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $43.67 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $42.55 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $42.55 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $42.55 | 2 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $40.20 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $39.79 | 3 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $39.79 | 3 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $32.49 | 3 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.73 | 1 | 2025 |
Source payment records
|
|||||
| ADSTILADRIN Normalized: adstiladrin |
Biological | Ferring Pharmaceuticals Inc. | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $26.94 | 2 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| IBTROZI Normalized: ibtrozi |
Drug | Nuvation Bio Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABOMETYX cabometyx |
2025 | Cabometyx | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CALQUENCE calquence |
2025 | Calquence | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ERLEADA erleada |
2025 | Erleada | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 39 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 39 |
| Exelixis Inc. Exact reporting entity; no affiliate inference |
2025 | CABOMETYX open payments reported associated product |
CMS Open Payments — General Payments 11749 supporting records · 4526 recipient NPIs · example record 1218789893 |
Cabometyx · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 790 supporting records · 308 recipient NPIs · example record 1174226359 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 302 | 71 |
| Potassium Chloride | Potassium Chloride | 219 | 75 |
| Eliquis | Apixaban | 199 | 39 |
| Gabapentin | Gabapentin | 180 | 47 |
| Letrozole | Letrozole | 143 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 49 |
| Prednisone | Prednisone | 131 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 24 |
| Acyclovir | Acyclovir | 98 | 27 |
| Hydroxyurea | Hydroxyurea | 97 | 19 |
| Levofloxacin | Levofloxacin | 88 | 60 |
| Ondansetron Odt | Ondansetron | 85 | 41 |
| Revlimid | Lenalidomide | 75 | 11 |
| Dexamethasone | Dexamethasone | 70 | 29 |
| Anastrozole | Anastrozole | 46 | 12 |
| Furosemide | Furosemide | 44 | 22 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Alprazolam | Alprazolam | 40 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Folic Acid | Folic Acid | 38 | 12 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | 11 |
| Olanzapine | Olanzapine | 33 | 23 |
| Xtandi | Enzalutamide | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 19 |
| Tramadol Hcl | Tramadol Hcl | 32 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 14 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 31 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Exemestane | Exemestane | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 14 |
| Morphine Sulfate | Morphine Sulfate | 24 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 12 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 23 | 19 |
| Cefuroxime | Cefuroxime Axetil | 22 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | 13 |
| Nystatin | Nystatin | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 20 |
| Calquence | Acalabrutinib Maleate | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Fluconazole | Fluconazole | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Lenalidomide | Lenalidomide | 19 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Erleada | Apalutamide | 18 | suppressed |
| Promacta | Eltrombopag Olamine | 18 | suppressed |
| Losartan Potassium | Losartan Potassium | 17 | suppressed |
| Bicalutamide | Bicalutamide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Deferasirox | Deferasirox | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Venclexta | Venetoclax | 16 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Metformin Hcl | Metformin Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Tasigna | Nilotinib Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,426.15 · 199 records | Merck Sharp & Dohme LLC | ADCETRIS, ADSTILADRIN, AKEEGA, AYVAKIT, BLENREP, BRAFTOVI, BRUKINSA, CABOMETYX, CALQUENCE, CARVYKTI, DANZITEN, DARZALEX, DATROWAY, Doptelet, ELIGARD, ELREXFIO, EMRELIS, ENHERTU, ENJAYMO, EPKINLY, ERLEADA, FOTIVDA, Fabhalta, GIVLAARI, Gavreto, IBRANCE, IBTROZI, IMBRUVICA, IMFINZI, INLYTA, INQOVI, JAKAFI, JAYPIRCA, KEYTRUDA, KEYTRUDA QLEX, KISQALI, Korlym, LIBTAYO, LONSURF, LUTATHERA, LYNOZYFIC, LYNPARZA, Lenvima, MEKTOVI, MONOFERRIC, NERLYNX, NINLARO, Nubeqa, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Onivyde, Orserdu, PADCEV, PLUVICTO, PROVENGE, PYRUKYND, QINLOCK, REBLOZYL, ROMVIMZA, RUBRACA, RYBREVANT, RYTELO, Rezlidhia, SCEMBLIX, Stivarga, TALVEY, TALZENNA, TAVALISSE, TECVAYLI, TGCT, TUKYSA, Trodelvy, VENCLEXTA, VERZENIO, Vanflyta, Vitrakvi, Vonjo, Vyloy, WELIREG, XPOVIO, XT CDX, XTANDI, Xofigo, ZEPZELCA, ZYNLONTA, ZYNYZ, Zoladex, clonoSEQ | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabometyx play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error